Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821Phase 3Active, not recruiting
- Lead sponsor
- BeOne Medicines (Industry)
- Enrollment
- 652 (estimated)
- Start date
- 11 Nov 2023
- Primary completion
- Feb 2032 (estimated)
- Study completion
- 1 Dec 2032
- Last update posted
- 14 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Sonrotoclax Drug
- Zanubrutinib Drug
- Venetoclax Drug
- Obinutuzumab Drug
Conditions and primary outcome
- CLL
Primary outcome
Cohort 1: Progression Free Survival (PFS） (Up to approximately 9 years); Cohort 1: Rate of Undetectable Measurable Residual Disease (Up to one and a half years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06073821.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06073821 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.